BAYER AG NA O.N.
Commented by Stefan Feulner on July 22nd, 2021 | 11:57 CEST
SAP, Deutsche Rohstoff, Bayer, Condor Gold - Better than expected
The reporting season for the second quarter of 2021 is in full swing. After the weak figures from the same period last year, caused by the Corona pandemic, analysts and investors expect significant earnings increases from companies that suffered heavy losses due to the global lockdowns. On the other hand, it will be interesting to see whether Corona beneficiaries such as Amazon can confirm their growth.
Read
Commented by Carsten Mainitz on July 20th, 2021 | 11:28 CEST
Mineworx Technologies, Siemens, Bayer - Innovation is the trump card
Since 2005, the Boston Consulting Group has annually selected the world's 50 most innovative companies. The list reads like a "Who's Who" of international heavyweights: Apple, Alphabet, Amazon, Microsoft and Tesla took the top 5 spots in 2021. In total, the United States was able to occupy 26 of the 50 spots - that is an impressive number. But German companies also find their way into the illustrious circle 9 times, including Siemens and Bayer. Why is innovation so important? Innovation is a key success factor for a company to achieve above-average results and differentiate itself from competitors. For this reason, we take a closer look at innovative companies in different industries. Who is your favorite?
Read
Commented by Armin Schulz on July 14th, 2021 | 10:54 CEST
Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?
One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.
Read
Commented by Stefan Feulner on July 13th, 2021 | 10:05 CEST
Bayer, Almonty Industries, Daimler - Shortages without end
The shortage of semiconductors weighs heavily on the auto industry. According to a study by the Duisburg-based Center for Automotive Research, it will be responsible for the loss of production of around five million vehicles this year alone. An end to the chip shortage is not yet in sight. Meanwhile, the next crisis due to the lack of raw materials is already just around the corner. Due to the rapid growth in electromobility, the high demand for lithium-ion batteries means that the next failures are pre-programmed.
Read
Commented by Nico Popp on July 6th, 2021 | 11:34 CEST
Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave
Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.
Read
Commented by Stefan Feulner on June 24th, 2021 | 12:52 CEST
CureVac, Cardiol Therapeutics, Bayer - Where we go from here
Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.
Read
Commented by Stefan Feulner on June 22nd, 2021 | 14:07 CEST
Steinhoff, Barsele Minerals, Bayer - This is explosive for the stock markets
Will the central banks change their direction, or will "the policy of cheap money" remain in place with unlimited bond purchases and zero interest rates to benefit growth? Last week, the markets were already caught on the wrong foot after the FED forecast two interest rate hikes for 2023. Then, the President of the St. Louis Fed, James Bullard, added even more salt to investors' wounds. He sees an accelerated tightening of monetary policy as a normal reaction to economic growth and rampant inflation in the wake of the economy's return from the Corona shock.
Read
Commented by Stefan Feulner on June 18th, 2021 | 11:34 CEST
Bayer, White Metal Resources, Barrick Gold - Trendsetting news
At Federal Reserve's meeting, runaway inflation was the topic par excellence. With US consumer prices up 5% in May, market participants assumed at least an announcement of a pullback in bond market volume. However, an interest rate hike, which would actually be necessary for price stability, is not considered before 2023, according to FED Chairman Jerome Powell. Thus, through the continued ultra-loose monetary policy, he refers to the attitude that economic growth and a rising stock market are more important than low inflation.
Read
Commented by Armin Schulz on June 16th, 2021 | 11:59 CEST
Barrick Gold, Triumph Gold, Bayer - is a golden summer coming?
An old stock market adage says: Sell in May and go away. In German: Sell your positions; in summer, the market will consolidate. There was a slight correction at the beginning of May, but the DAX has been climbing since then. It is currently trying to reach the 16,000 point mark. The price of gold recently traded above USD 1,900 for the first time again, which can certainly be understood as a sign that investors want to secure their money from inflation. While the US Federal Reserve emphasized that it does not want to take any countermeasures for the time being, the US Treasury Secretary Yellen recently surprised with the statement that higher interest rates would be good for the United States. It remains exciting. There is the possibility of a golden summer on the markets.
Read
Commented by Nico Popp on June 15th, 2021 | 13:15 CEST
CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio
Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.
Read